The elucidation of the mechanism in cancer microenvironment by ovarian cancer secretion exosome and the development of a next-generation cancer therapy by the exosome.

• Project/Area Number: 26462541
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Osaka Medical College
• Principal Investigator: SASAKI HIROSHI 大阪医科大学, 医学部, 講師 (80432491)
• Co-Investigator(Kenkyū-buntansha): 大道 正英 大阪医科大学, 医学部, 教授 (10283764) ; 田中 良道 大阪医科大学, 医学部, 講師 (10625502) ; 金村 昌徳 大阪医科大学, 医学部, 非常勤講師 (40298782) ; 恒遠 啓示 大阪医科大学, 医学部, 講師 (70388255) ; 田辺 晃子 大阪医科大学, 医学部, 非常勤講師 (70454543) ; 寺井 義人 大阪医科大学, 医学部, 准教授 (90278531) ; 藤原 聡枝 大阪医科大学, 医学部, 助教 (90707960)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: エキソソーム / 卵巣癌 / 癌微小環境 / microRNA

Outline of Final Research Achievements

There are micro RNA and the small molecule protein as a convenient communication of information tool in the extracellular vesicles and exosome covered by the lipid bilayer membrane secreted from an ovarian cancer. We isolated exosome from the ovarian cancer patient's ascites and ovarian-veins serum, and extracted microRNA from exosome. Mir-34a related to the EpithelialMesenchymal Transition(EMT). Moreover, the expression
of CD24 which is the EMT related protein in ovarian cancer is prognosis prediction marker for ovarian cancer patients.

Research Products

• [Journal Article] The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. (2017)
  • Author(s): anaka T, Terai Y, Ashihara K, Fujiwara S, Tanaka Y, Sasaki H, Tsunetoh S, Ohmichi M
  • Journal Title: PLoS One Volume: 12 Issue: 5 Pages: e0177019-e0177019
  • DOI: 10.1371/journal.pone.0177019
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways. (2017)
  • Author(s): Nakamura K, Terai Y, Tanabe A, Ono YJ, Hayashi M, Maeda K, Fujiwara S, Ashihara K, Nakamura M, Tanaka Y, Tanaka T, Tsunetoh S, Sasaki H, Ohmichi M.
  • Journal Title: Oncol Rep Volume: - Issue: 6 Pages: 3189-3200
  • DOI: 10.3892/or.2017.5583
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer. (2014)
  • Author(s): Kawaguchi H, Terai Y, Tanabe A, Sasaki H, Takai M, Fujiwara S, Ashihara K, Tanaka Y, Tanaka T, Tsunetoh S, Kanemura M, Ohmichi M.
  • Journal Title: J Ovarian Res. Volume: 7 Issue: 1 Pages: 38-38
  • DOI: 10.1186/1757-2215-7-38
  • Peer Reviewed / Open Access
• [Journal Article] The EMT (epithelial mesenchymaltransition protein expression indicates the metastasicc status and progesis in patient with ovarian cancer (2014)
  • Author(s): Takai M, Terai Y, Kawaguchi H, Ashihara K, Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M, Tanabe A, Ohmichi M.
  • Journal Title: Journal of ovarian research Volume: 76 Issue: 1 Pages: 1-5
  • DOI: 10.1186/1757-2215-7-76
  • Peer Reviewed / Open Access